Passive immunization against HIV/AIDS by antibody gene transfer.
Despite tremendous efforts over the course of many years, the quest for an effective HIV vaccine by the classical method of active immunization remains largely elusive. However, two recent studies in mice and macaques have now demonstrated a new strategy designated as Vectored ImmunoProphylaxis (VIP), which involves passive immunization by viral vector-mediated delivery of genes encoding broadly neutralizing antibodies (bnAbs) for in vivo expression. Robust protection against virus infection was observed in preclinical settings when animals were given VIP to express monoclonal neutralizing antibodies. This unorthodox approach raises new promise for combating the ongoing global HIV pandemic. In this article, we survey the status of antibody gene transfer, review the revolutionary progress on isolation of extremely bnAbs, detail VIP experiments against HIV and its related virus conduced in humanized mice and macaque monkeys, and discuss the pros and cons of VIP and its opportunities and challenges towards clinical applications to control HIV/AIDS endemics.
Department of Microbiology, Immunology and Molecular Genetics, Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California at Los Angeles, Los Angeles, CA 90095, USA. liliyang@ucla.edu.
Lili
L
Yang
Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA. pinwang@usc.edu.
Pin
P
Wang
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology*; D004195:Disease Models, Animal; D015316:Genetic Therapy / Q000379:methods*; D015483:HIV Antibodies / Q000235:genetics / Q000276:immunology*; D007116:Immunization, Passive / Q000379:methods*; D008251:Macaca; D051379:Mice; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies